Kiniksa Pharmaceuticals (KNSA) Stock Forecast, Price Target & Predictions
KNSA Stock Forecast
Kiniksa Pharmaceuticals stock forecast is as follows: an average price target of $36.33 (represents a 69.13% upside from KNSA’s last price of $21.48) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
KNSA Price Target
KNSA Analyst Ratings
Kiniksa Pharmaceuticals Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Oct 29, 2024 | Liisa Bayko | Evercore ISI | $35.00 | $23.27 | 50.44% | 62.94% |
Sep 13, 2024 | Roger Song | Jefferies | $40.00 | $24.49 | 63.33% | 86.22% |
May 03, 2024 | Eva Fortea Verdejo | Wells Fargo | $34.00 | $19.38 | 75.44% | 58.29% |
Kiniksa Pharmaceuticals Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 2 | 3 |
Avg Price Target | $35.00 | $37.50 | $36.33 |
Last Closing Price | $21.48 | $21.48 | $21.48 |
Upside/Downside | 62.94% | 74.58% | 69.13% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 29, 2024 | Evercore ISI | Outperform | Outperform | Hold |
Sep 13, 2024 | Jefferies | - | Buy | Initialise |
Jul 24, 2024 | Wells Fargo | Overweight | Overweight | Hold |
May 03, 2024 | Wells Fargo | - | Overweight | Initialise |
Kiniksa Pharmaceuticals Financial Forecast
Kiniksa Pharmaceuticals Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | $67.05M | $71.47M | $48.34M | $61.88M | $99.14M | $26.97M | $32.19M | $18.75M | $12.10M | $7.70M | - |
Avg Forecast | $155.40M | $151.80M | $140.75M | $138.41M | $122.44M | $111.51M | $90.60M | $76.97M | $73.25M | $64.55M | $52.06M | $46.61M | $45.12M | $93.58M | $28.42M | $30.10M | $17.60M | $10.26M | $4.29M | $7.78M |
High Forecast | $162.24M | $158.48M | $146.94M | $141.62M | $124.35M | $116.42M | $90.85M | $76.97M | $74.13M | $64.55M | $54.35M | $48.66M | $47.10M | $93.58M | $28.42M | $30.10M | $17.60M | $10.26M | $4.29M | $7.78M |
Low Forecast | $148.55M | $145.12M | $134.55M | $135.20M | $119.33M | $106.60M | $90.35M | $76.97M | $72.38M | $64.55M | $49.77M | $44.56M | $43.13M | $93.58M | $28.42M | $30.10M | $17.60M | $10.26M | $4.29M | $7.78M |
# Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Surprise % | - | - | - | - | - | - | - | - | - | 1.04% | 1.37% | 1.04% | 1.37% | 1.06% | 0.95% | 1.07% | 1.07% | 1.18% | 1.80% | - |
Kiniksa Pharmaceuticals EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EBITDA | - | - | - | - | - | - | - | - | - | $-10.93M | $-3.15M | $-11.20M | $6.05M | $46.41M | $-19.37M | $-23.32M | $-35.39M | $-30.00M | $-39.83M | $-48.96M |
Avg Forecast | $29.80M | $29.11M | $26.99M | $26.55M | $23.48M | $21.39M | $17.38M | $-22.20M | $14.05M | $12.38M | $9.99M | $-23.74M | $-24.42M | $17.95M | $5.45M | $-25.39M | $3.38M | $1.97M | $823.11K | $-48.97M |
High Forecast | $31.12M | $30.40M | $28.18M | $27.16M | $23.85M | $22.33M | $17.43M | $-17.76M | $14.22M | $12.38M | $10.42M | $-18.99M | $-19.54M | $17.95M | $5.45M | $-20.31M | $3.38M | $1.97M | $823.11K | $-39.18M |
Low Forecast | $28.49M | $27.83M | $25.80M | $25.93M | $22.89M | $20.44M | $17.33M | $-26.63M | $13.88M | $12.38M | $9.55M | $-28.49M | $-29.30M | $17.95M | $5.45M | $-30.47M | $3.38M | $1.97M | $823.11K | $-58.77M |
Surprise % | - | - | - | - | - | - | - | - | - | -0.88% | -0.32% | 0.47% | -0.25% | 2.59% | -3.55% | 0.92% | -10.48% | -15.25% | -48.39% | 1.00% |
Kiniksa Pharmaceuticals Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Net Income | - | - | - | - | - | - | - | - | - | $-13.86M | $14.97M | $-12.27M | $4.46M | $224.09M | $-19.98M | $-25.21M | $-36.33M | $-30.54M | $-41.56M | $-49.48M |
Avg Forecast | $13.27M | $10.04M | $5.98M | $6.22M | $3.73M | $1.67M | $-5.51M | $-24.73M | $-7.06M | $-11.89M | $-10.16M | $-26.45M | $-25.07M | $33.65M | $-32.31M | $-28.28M | $-29.09M | $-45.93M | $-60.12M | $-49.48M |
High Forecast | $14.03M | $10.62M | $6.32M | $13.99M | $16.16M | $1.77M | $-5.20M | $-19.78M | $-2.57M | $-11.21M | $-9.58M | $-21.16M | $-20.06M | $33.65M | $-32.31M | $-22.63M | $-29.09M | $-45.93M | $-60.12M | $-39.59M |
Low Forecast | $12.51M | $9.47M | $5.63M | $-3.11M | $-7.46M | $1.58M | $-5.83M | $-29.67M | $-11.55M | $-12.57M | $-10.74M | $-31.74M | $-30.09M | $33.65M | $-32.31M | $-33.94M | $-29.09M | $-45.93M | $-60.12M | $-59.38M |
Surprise % | - | - | - | - | - | - | - | - | - | 1.17% | -1.47% | 0.46% | -0.18% | 6.66% | 0.62% | 0.89% | 1.25% | 0.67% | 0.69% | 1.00% |
Kiniksa Pharmaceuticals SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
SG&A | - | - | - | - | - | - | - | - | - | $34.47M | $29.18M | $29.05M | $27.21M | $24.68M | $23.84M | $22.22M | $22.74M | $20.76M | $21.85M | $20.60M |
Avg Forecast | $160.17M | $156.47M | $145.07M | $142.66M | $126.20M | $114.94M | $93.38M | $21.79M | $75.51M | $66.54M | $53.66M | $23.31M | $15.69M | $96.45M | $29.29M | $24.93M | $18.14M | $10.57M | $4.42M | $8.01M |
High Forecast | $167.22M | $163.35M | $151.46M | $145.97M | $128.17M | $119.99M | $93.65M | $26.15M | $76.40M | $66.54M | $56.02M | $27.97M | $18.83M | $96.45M | $29.29M | $29.91M | $18.14M | $10.57M | $4.42M | $8.01M |
Low Forecast | $153.12M | $149.57M | $138.68M | $139.35M | $123.00M | $109.87M | $93.12M | $17.43M | $74.61M | $66.54M | $51.30M | $18.65M | $12.56M | $96.45M | $29.29M | $19.94M | $18.14M | $10.57M | $4.42M | $8.01M |
Surprise % | - | - | - | - | - | - | - | - | - | 0.52% | 0.54% | 1.25% | 1.73% | 0.26% | 0.81% | 0.89% | 1.25% | 1.96% | 4.94% | 2.57% |
Kiniksa Pharmaceuticals EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EPS | - | - | - | - | - | - | - | - | - | $-0.20 | $0.21 | $-0.18 | $0.06 | $3.23 | $-0.29 | $-0.36 | $-0.53 | $-0.44 | $-0.61 | $-0.72 |
Avg Forecast | $0.18 | $0.14 | $0.08 | $0.09 | $0.05 | $0.02 | $-0.08 | $-0.08 | $-0.10 | $-0.17 | $-0.14 | $-0.16 | $-0.20 | $0.47 | $-0.46 | $-0.43 | $-0.41 | $-0.65 | $-0.85 | $-0.72 |
High Forecast | $0.20 | $0.15 | $0.09 | $0.20 | $0.23 | $0.02 | $-0.07 | $-0.08 | $-0.04 | $-0.16 | $-0.13 | $-0.15 | $-0.19 | $0.47 | $-0.46 | $-0.43 | $-0.41 | $-0.65 | $-0.85 | $-0.72 |
Low Forecast | $0.17 | $0.13 | $0.08 | $-0.04 | $-0.10 | $0.02 | $-0.08 | $-0.09 | $-0.16 | $-0.18 | $-0.15 | $-0.17 | $-0.21 | $0.47 | $-0.46 | $-0.43 | $-0.41 | $-0.65 | $-0.85 | $-0.72 |
Surprise % | - | - | - | - | - | - | - | - | - | 1.21% | -1.48% | 1.13% | -0.30% | 6.82% | 0.64% | 0.84% | 1.29% | 0.68% | 0.72% | 0.99% |
Kiniksa Pharmaceuticals Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
VTYX | Ventyx Biosciences | $2.15 | $33.86 | 1474.88% | Buy |
CHRS | Coherus BioSciences | $0.67 | $9.00 | 1243.28% | Hold |
KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
SPRO | Spero Therapeutics | $1.29 | $10.00 | 675.19% | Buy |
GOSS | Gossamer Bio | $0.89 | $3.75 | 321.35% | Buy |
LRMR | Larimar Therapeutics | $7.57 | $20.33 | 168.56% | Buy |
DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
GPCR | Structure Therapeutics | $39.74 | $92.40 | 132.51% | Buy |
REPL | Replimune Group | $12.02 | $24.20 | 101.33% | Buy |
CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
LYRA | Lyra Therapeutics | $0.26 | $0.50 | 92.31% | Hold |
KNSA | Kiniksa Pharmaceuticals | $21.48 | $36.33 | 69.13% | Buy |
COGT | Cogent Biosciences | $11.87 | $18.83 | 58.64% | Buy |
BOLT | Bolt Biotherapeutics | $0.67 | $1.00 | 49.25% | Hold |
KURA | Kura Oncology | $17.81 | $26.00 | 45.99% | Buy |
PHAT | Phathom Pharmaceuticals | $18.94 | $25.83 | 36.38% | Buy |
NUVL | Nuvalent | $89.53 | $107.83 | 20.44% | Buy |
ACLX | Arcellx | $86.44 | $71.57 | -17.20% | Buy |
KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
KNSA Forecast FAQ
Is Kiniksa Pharmaceuticals a good buy?
Yes, according to 3 Wall Street analysts, Kiniksa Pharmaceuticals (KNSA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of KNSA's total ratings.
What is KNSA's price target?
Kiniksa Pharmaceuticals (KNSA) average price target is $36.33 with a range of $34 to $40, implying a 69.13% from its last price of $21.48. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Kiniksa Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for KNSA stock, the company can go up by 69.13% (from the last price of $21.48 to the average price target of $36.33), up by 86.22% based on the highest stock price target, and up by 58.29% based on the lowest stock price target.
Can Kiniksa Pharmaceuticals stock reach $30?
KNSA's average twelve months analyst stock price target of $36.33 supports the claim that Kiniksa Pharmaceuticals can reach $30 in the near future.
What is Kiniksa Pharmaceuticals's current price target trend?
1 Wall Street analyst forecast a $35 price target for Kiniksa Pharmaceuticals (KNSA) this month, up 62.94% from its last price of $21.48. Compared to the last 3 and 12 months, the average price target increased by 74.58% and increased by 69.13%, respectively.
What are Kiniksa Pharmaceuticals's analysts' financial forecasts?
Kiniksa Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $401.52M (high $408.6M, low $393.25M), average EBITDA is $40.05M (high $45.85M, low $34.03M), average net income is $-24.838M (high $-7.049M, low $-41.384M), average SG&A $356.31M (high $367.96M, low $343.43M), and average EPS is $-0.0837 (high $0.1, low $-0.25). KNSA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $586.36M (high $609.28M, low $563.41M), average EBITDA is $112.46M (high $116.85M, low $108.06M), average net income is $35.5M (high $44.95M, low $24.5M), average SG&A $604.37M (high $628M, low $580.72M), and average EPS is $0.495 (high $0.627, low $0.342).
Did the KNSA's actual financial results beat the analysts' financial forecasts?
Based on Kiniksa Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $270.26M, beating the average analysts forecast of $236.48M by 14.28%. Apple's EBITDA was $-25.196M, missing the average prediction of $12.68M by -298.74%. The company's net income was $-47.388M, missing the average estimation of $-55.555M by -14.70%. Apple's SG&A was $129.43M, missing the average forecast of $219.01M by -40.90%. Lastly, the company's EPS was $-0.0007, missing the average prediction of $-0.565 by -99.88%. In terms of the last quarterly report (Sep 2023), Kiniksa Pharmaceuticals's revenue was $67.05M, beating the average analysts' forecast of $64.55M by 3.86%. The company's EBITDA was $-10.927M, missing the average prediction of $12.38M by -188.26%. Kiniksa Pharmaceuticals's net income was $-13.855M, beating the average estimation of $-11.892M by 16.51%. The company's SG&A was $34.47M, missing the average forecast of $66.54M by -48.20%. Lastly, the company's EPS was $-0.2, beating the average prediction of $-0.166 by 20.63%